VaramirStart free · no cardSign in
XENE as of Nov 1 · 20:05 ET
XENENasdaqPharmaceutical Preparations

Xenon Pharmaceuticals Inc. · Brief

Next report

Today

Nov 2 · after closeest.Q3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
1 of 8≥ implied
avg implied
±11.8%
avg realized
±5.1%
Nov 12 '24±6.1%▼−3.27%×0.54
Feb 27 '25±11.0%▼−3.37%×0.31
May 12 '25±12.0%▼−17.43%×1.45
Aug 11 '25±7.3%▲+5.51%×0.75
Nov 3 '25±8.7%▼−4.94%×0.57
Q1 FY26±30.3%▼−3.76%×0.12
May 7 '26±10.3%▲+0.79%×0.08
Q2 FY26±9.1%▼−1.84%×0.20
quarterimplied−35%0+35%realized×
Q2 FY26±9.1%▼−1.84%×0.20
May '26±10.3%▲+0.79%×0.08
Q1 FY26±30.3%▼−3.76%×0.12
Nov '25±8.7%▼−4.94%×0.57
Aug '25±7.3%▲+5.51%×0.75
May '25±12.0%▼−17.43%×1.45
2 older reports
Feb '25±11.0%▼−3.37%×0.31
Nov '24±6.1%▼−3.27%×0.54
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 2 report · est.

Bull2

316managers reporting a position in the latest quarterly filings13F · Jun 30 '26
+11.50%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26

Bear1

8 of 24of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

XENE report session

Customers 1

NBIXNeurocrine Biosciences×0.18
× = co-movement · max 499dSource: SEC filings · market data

Latest changes

30 daysAll changes
Oct 19impliedImplied move: ±8.8% into Nov 2 earnings (Oct 19 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.